Tinea pedis
Conditions
Interventions
Administer orally once daily for 4 weeks either a capsule containing 100 mg of hoslabconazole or a placebo capsule.
Sponsors
Kataoka Hiroya
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Patients with tinea pedis in both feet or either foot. - Patients who have been confirmed to have dermatophyte elements by direct microscopic examination. - Patients in whom dermatophytes (Trichophyton species) have been identified by fungal culture. - Japanese patients aged 18 years or older at the time of consent.
Exclusion criteria
Exclusion criteria: - Patients with clinically significant hepatic dysfunction. - Patients with diseases or symptoms other than tinea pedis in the foot to be evaluated. - Patients who have used oral antifungal agents within 12 weeks prior to obtaining consent, or who are currently using them. - Patients who have used topical antifungal agents or topical treatments for onychomycosis on the foot to be evaluated within 4 weeks prior to obtaining consent, or who are currently using them.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cure rate at 12 weeks after the start of treatment. | — |
Contacts
Public ContactClinical Trials Information Desk
Sato Pharmaceutical Co., Ltd.
Outcome results
None listed